STATENS SERUM INSTITUT

Patent Owner

Compare Create Portfolio

Stats

Details

Technologies

Intl Class Technology # of Patents/ App Rank in Class
 
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 26222
 
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4163
 
 
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 382
 
 
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 395
 
 
 
C07K PEPTIDES 3110
 
 
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 3115
 
 
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 292
 
 
 
C12M APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY 144
 
 
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 1146
 
 
 
C40B COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES, IN SILICO LIBRARIES 131

Top Patents (by citation)

Upgrade to the Premium Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2014/0205,656 MODIFIED CATIONIC LIPOSOME ADJUVANTSJan 23, 14Jul 24, 14[A61K]
2014/0170,182 PRODUCTION OF A CYSTEINE RICH PROTEINOct 03, 12Jun 19, 14[C07K]
2014/0154,696 PCR DIAGNOSTICS OF DERMATOPHYTES AND OTHER PATHOGENIC FUNGIFeb 07, 14Jun 05, 14[C12N, C12Q]
2014/0112,979 METHODS FOR PRODUCING LIPOSOMESJul 03, 12Apr 24, 14[A61K]
2013/0149,324 THERAPEUTIC TB VACCINEFeb 09, 12Jun 13, 13[C07K]
2013/0095,132 TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASESep 20, 12Apr 18, 13[C07K]
2012/0208,714 DNA-BASED METHODS FOR CLONE-SPECIFIC IDENTIFICATION OF STAPHYLOCOCCUS AUREUSJun 17, 10Aug 16, 12[C40B, C12Q]
2012/0156,282 EXPANDING THE T CELL REPERTOIRE TO INCLUDE SUBDOMINANT EPITOPES BY VACCINATION WITH ANTIGENS DELIVERED AS PROTEIN FRAGMENTS OR PEPTIDE COCKTAILSDec 16, 11Jun 21, 12[C12P, A61P, A61K]
2012/0114,687 TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASEDec 22, 11May 10, 12[C07H, A61P, A61K, C07K]
2012/0039,925 TUBERCULOSIS TB VACCINE TO PREVENT REACTIVATIONApr 23, 10Feb 16, 12[C07H, A61P, A61K, C07K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
8,753,875 Compositions and means for diagnosing microbial infectionsNov 04, 08Jun 17, 14[C12M]
8,703,151 Tuberculosis vaccines comprising antigens expressed during the latent infection phaseSep 20, 12Apr 22, 14[C07H, A61K]
8,563,009 Use of monomycolyl glycerol (MMG) as an adjuvantJun 26, 08Oct 22, 13[A61K]
8,557,258 Vaccines comprising TB10.4Aug 30, 11Oct 15, 13[A61K]
8,293,250 Tuberculosis vaccines comprising antigens expressed during the latent infection phaseDec 22, 11Oct 23, 12[C07H, A61K]
8,288,090 Influenza vaccinesJan 19, 10Oct 16, 12[C12Q]
8,277,823 Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipidsMay 21, 10Oct 02, 12[A61K]
8,241,610 Adjuvant combinations of liposomes and mycobacterial lipids for immunization compositions and vaccinesApr 08, 11Aug 14, 12[A61B, A61K]
8,142,797 Therapeutic TB vaccineMay 21, 10Mar 27, 12[A61K]
8,114,609 ADAM12, a novel marker for abnormal cell functionFeb 02, 10Feb 14, 12[G01N, C07K]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Filing Date Issue/Pub Date Intl Class
2013/0149,324 THERAPEUTIC TB VACCINEFeb 09, 12Jun 13, 13[C07K]
2011/0287,087 MODIFIED CATIONIC LIPOSOME ADJUVANSNov 10, 09Nov 24, 11[A61P, A61K]
2011/0020,387 MALARIA VACCINEJun 03, 10Jan 27, 11[C12N, C12P, A61P, A61K, C07K]
2010/0311,041 PCR DIAGNOSTICS OF DERMATOPHYTES AND OTHER PATHOGENIC FUNGIJun 13, 06Dec 09, 10[C07H, C12Q]
2010/0015,171 VACCINES COMPRISING TB 10.4Jul 10, 09Jan 21, 10[A61P, A61K, C07K]
2008/0299,151 Influenza vaccinesMay 30, 08Dec 04, 08[A61P, A61K]
2007/0184,073 TB diagnostic based on antigens from M. tuberculosisAug 02, 05Aug 09, 07[C12N, C07H, C12Q, A61K, C07K]
2006/0194,206 Diagnostics of diarrheagenic escherichia coli (dec) and shigella sppJul 09, 04Aug 31, 06[C12Q]
6,982,085 TB diagnostic based on antigens from M. tuberculosisMay 02, 02Jan 03, 06[C12N, A61K]
6,921,808 Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc-globulin and a Gc-globulin medicinal productAug 18, 04Jul 26, 05[C07K]
6,806,355 Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal productAug 13, 02Oct 19, 04[C07K]
2004/0086,949 Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereofDec 01, 03May 06, 04[G01N, C07K]
2004/0072,162 Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infectionApr 10, 03Apr 15, 04[C12Q, G06F, G01N]
2004/0057,963 Therapeutic TB vaccineJul 11, 03Mar 25, 04[A61K]
2004/0018,574 Molecular differences between species of the M. tuberculosis complexMar 14, 03Jan 29, 04[A61K, G01N, C07K]
2004/0013,685 Nucleic acid fragments and polypeptide fragments derived from M. tuberculosisJun 01, 01Jan 22, 04[C12N, C07H, C12P, A61K, C07K]
6,649,409 Method for producing a nucleotide sequence construct with optimized codons for an HIV genetic vaccine based on a primary, early HIV isolate and synthetic envelope BX08 constructsMar 29, 00Nov 18, 03[C12N, C07H, C12P, A61K]
6,641,814 Nucleic acids fragments and polypeptide fragments derived from M. tuberculosisMar 30, 98Nov 04, 03[C12N, C12M, A61K]
2003/0065,039 Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-onesJan 31, 02Apr 03, 03[A61K]
2002/0094,336 Nucleic acid fragments and polypeptide fragments derived from M. tuberculosisFeb 20, 01Jul 18, 02[C12N, A61K]

View all patents..

Top Inventors for This Owner

Upgrade to the Premium Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.